Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

NCT06700343 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

444

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing-remitting Multiple Sclerosis (RRMS)

Interventions

DRUG: Ocrelizumab (US)
DRUG: Ocrelizumab (EU)
DRUG: ABP 692

Sponsor

Amgen